![Daphne Karydas](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Daphne Karydas
Directeur/Membre du Conseil chez
MINERALYS THERAPEUTICS, INC.
Fortune : 195 300 $ au 31/05/2026
Profil
Daphne Karydas is the founder of Eucrates Biomedical Acquisition Corp., founded in 2020, and served as Independent Director from 2020 to 2023.
Ms. Karydas currently holds positions as Independent Director at Compass Pathways Plc since 2023, Independent Director at Mineralys Therapeutics, Inc. since 2023, and President & Chief Financial Officer at Flare Therapeutics, Inc. since 2021.
Former positions include Executive Director at JPMorgan Investment Management, Inc. from 2015 to 2017, Independent Director at Elicio Therapeutics, Inc., Independent Director at LogicBio Therapeutics, Inc. from 2020 to 2022, Portfolio Manager & Senior Analyst at The Boston Company Asset Management LLC from 2011 to 2014, Vice President at BNY Mellon Investment Adviser, Inc., Project Chemical Engineer at Merck & Co., Inc., Vice President at Goldman Sachs Asset Management LP in 2006, Chief Financial Officer at Syndax Pharmaceuticals, Inc. from 2020 to 2021, Associate at Goldman Sachs & Co. LLC.
from 2000 to 2003,.
and Senior VP-Corporate Financial Planning & Analysis at Allergan UC from 2018 to 2020.
Education includes undergraduate and graduate degrees from Massachusetts Institute of Technology, and an MBA from Harvard Business School conferred in 2000.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2026 | 6 200 ( 0,01 % ) | 195 300 $ | 31/05/2026 | |
COMPASS PATHWAYS PLC -.--% | 27/05/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Daphne Karydas
| Sociétés | Poste | Début |
|---|---|---|
| MINERALYS THERAPEUTICS, INC. | Directeur/Membre du Conseil | 13/09/2023 |
| COMPASS PATHWAYS PLC | Directeur/Membre du Conseil | 18/09/2023 |
Flare Therapeutics, Inc.
 Flare Therapeutics, Inc. BiotechnologyHealth Technology Engages in research and development of small molecule medicines | Directeur Financier/CFO | 26/10/2021 |
Anciens postes connus de Daphne Karydas
| Sociétés | Poste | Fin |
|---|---|---|
| LOGICBIO THERAPEUTICS, INC. | Directeur/Membre du Conseil | 16/11/2022 |
| SYNDAX PHARMACEUTICALS, INC. | Directeur Financier/CFO | 22/10/2021 |
| ALLERGAN PLC | Public Communications Contact | 10/12/2018 |
JPMorgan Investment Management, Inc.
 JPMorgan Investment Management, Inc. Investment ManagersFinance JPMIM seeks to generate positive excess return through both a bottom-up approach emphasizing security selection and a top-down approach focusing on macro investment themes and trends to aid in determining sector weightings, currency, and yield curve weighting where appropriate. The firm offers a broad range of US, non-US and global investment management products and provides different strategies that span the full spectrum of asset classes including equity, fixed-income, cash liquidity, currency, real estate, hedge funds and private equity. | Analyst-Equity | 01/04/2017 |
The Boston Company Asset Management LLC
 The Boston Company Asset Management LLC Investment ManagersFinance The Boston Company Asset Management (TBCAM) offers both traditional and alternative equity investment products that encompass a variety of US, non-US and global strategies. The firm provides investment advice for the following types of strategies: US domestic equity, balanced, non-US equity, emerging markets equity and long/short equity. Portfolios generally are composed of individual securities. TBCAM seeks consistent delivery of alpha across a broad range of investment strategies. They are committed to a value-oriented, research-driven and risk-aware investment approach. TBCAM seeks to identify attractive stocks through rigorous quantitative and fundamental analyses blended with analysis of current business momentum and places controls on sector selection and, if applicable, country selection. Short sales and similar strategies are considered part of their overall investment strategy; however, they are not used across the account base in the management of account assets. The firm may use these strategies for certain accounts consistent with the client's guidelines, objectives, and restrictions. | Analyst-Equity | 01/12/2014 |
Formation de Daphne Karydas
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
97
Relations au 1er degré
16
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 16 |
|---|---|
The Boston Company Asset Management LLC
The Boston Company Asset Management LLC Investment ManagersFinance The Boston Company Asset Management (TBCAM) offers both traditional and alternative equity investment products that encompass a variety of US, non-US and global strategies. The firm provides investment advice for the following types of strategies: US domestic equity, balanced, non-US equity, emerging markets equity and long/short equity. Portfolios generally are composed of individual securities. TBCAM seeks consistent delivery of alpha across a broad range of investment strategies. They are committed to a value-oriented, research-driven and risk-aware investment approach. TBCAM seeks to identify attractive stocks through rigorous quantitative and fundamental analyses blended with analysis of current business momentum and places controls on sector selection and, if applicable, country selection. Short sales and similar strategies are considered part of their overall investment strategy; however, they are not used across the account base in the management of account assets. The firm may use these strategies for certain accounts consistent with the client's guidelines, objectives, and restrictions. | Finance |
BNY Mellon Investment Adviser, Inc.
 BNY Mellon Investment Adviser, Inc. Investment ManagersFinance BNYMIA’s investment approach is a team approach where portfolio managers and the research team share information to form a disciplined and consistent strategy that meets the client’s diversification, credit quality, liquidity and average weighted maturity requirements. The firm’s credit research function is fully independent from portfolio management and their dedicated research team employs a deliberately conservative policy, when evaluating individual credits, to help support portfolio credit quality and stability. | Finance |
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
JPMorgan Investment Management, Inc.
JPMorgan Investment Management, Inc. Investment ManagersFinance JPMIM seeks to generate positive excess return through both a bottom-up approach emphasizing security selection and a top-down approach focusing on macro investment themes and trends to aid in determining sector weightings, currency, and yield curve weighting where appropriate. The firm offers a broad range of US, non-US and global investment management products and provides different strategies that span the full spectrum of asset classes including equity, fixed-income, cash liquidity, currency, real estate, hedge funds and private equity. | Finance |
Goldman Sachs Asset Management LP
 Goldman Sachs Asset Management LP Investment ManagersFinance GSMALP offers a wide array of investment strategies that span asset classes, industries, and geographies. The firm's products and services across a full range of asset classes including fixed income, money markets, public and private equity, commodities, hedge funds, and real estate. Clients access these solutions through GSAM's proprietary strategies, strategic partnerships, and open architecture programs. | Finance |
Syndax Pharmaceuticals, Inc.
 Syndax Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Elicio Therapeutics, Inc. (United States)
 Elicio Therapeutics, Inc. (United States) BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel immunotherapies for treatment of cancer and other diseases | Health Technology |
Goldman Sachs & Co. LLC
 Goldman Sachs & Co. LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Allergan Ltd. (Ireland)
 Allergan Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes pharmaceuticals, devices, biological, surgical & regenerative medicine products | Health Technology |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines and therapies for bone metabolism, cardiology, neurology and rare diseases | Health Technology |
Compass Pathways Plc
 Compass Pathways Plc BiotechnologyHealth Technology Develops therapies and drugs for the treatment of mental health and neurocognitive conditions | Health Technology |
Eucrates Biomedical Acquisition Corp.
 Eucrates Biomedical Acquisition Corp. Financial ConglomeratesFinance Operates as an blank check company | Finance |
Mineralys Therapeutics, Inc.
 Mineralys Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops medicines to target diseases | Health Technology |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Engages in research and development of small molecule medicines | Health Technology |
